CN102822332A - 从源于人胚胎干细胞的成血管细胞产生自然杀伤细胞和树突细胞的方法 - Google Patents

从源于人胚胎干细胞的成血管细胞产生自然杀伤细胞和树突细胞的方法 Download PDF

Info

Publication number
CN102822332A
CN102822332A CN2010800629687A CN201080062968A CN102822332A CN 102822332 A CN102822332 A CN 102822332A CN 2010800629687 A CN2010800629687 A CN 2010800629687A CN 201080062968 A CN201080062968 A CN 201080062968A CN 102822332 A CN102822332 A CN 102822332A
Authority
CN
China
Prior art keywords
cell
cells
concentration
angioplast
scf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800629687A
Other languages
English (en)
Chinese (zh)
Inventor
E·金步雷尔
S-J·鲁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stem Cell and Regenerative Medicine International Inc
Original Assignee
Stem Cell and Regenerative Medicine International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell and Regenerative Medicine International Inc filed Critical Stem Cell and Regenerative Medicine International Inc
Publication of CN102822332A publication Critical patent/CN102822332A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN2010800629687A 2009-12-04 2010-12-01 从源于人胚胎干细胞的成血管细胞产生自然杀伤细胞和树突细胞的方法 Pending CN102822332A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26666109P 2009-12-04 2009-12-04
US61/266,661 2009-12-04
PCT/US2010/058593 WO2011068896A1 (en) 2009-12-04 2010-12-01 Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts

Publications (1)

Publication Number Publication Date
CN102822332A true CN102822332A (zh) 2012-12-12

Family

ID=44115272

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800629687A Pending CN102822332A (zh) 2009-12-04 2010-12-01 从源于人胚胎干细胞的成血管细胞产生自然杀伤细胞和树突细胞的方法

Country Status (11)

Country Link
US (3) US8822218B2 (https=)
EP (1) EP2507365A4 (https=)
JP (5) JP6013187B2 (https=)
KR (5) KR20250048382A (https=)
CN (1) CN102822332A (https=)
AU (1) AU2010326027A1 (https=)
BR (1) BR112012014104A2 (https=)
CA (3) CA3095576A1 (https=)
IN (1) IN2012DN05053A (https=)
RU (1) RU2012127811A (https=)
WO (1) WO2011068896A1 (https=)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822218B2 (en) 2009-12-04 2014-09-02 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
CN104711225A (zh) * 2015-04-09 2015-06-17 奥思达干细胞有限公司 Nk细胞的体外制备方法
CN105219716A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活头颈部癌特异性免疫反应的试剂盒
CN105219710A (zh) * 2014-06-05 2016-01-06 上海厚超生物科技有限公司 一种高杀伤活性的免疫细胞群的培养方法
CN105219717A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种一型极化树突状细胞及其诱导方法和应用
CN105219723A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活胃癌特异性免疫反应的试剂盒
CN105219719A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活卵巢癌特异性免疫反应的试剂盒
CN105219722A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活肾癌特异性免疫反应的试剂盒
CN105219718A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活前列腺癌特异性免疫反应的试剂盒
CN105219726A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种高效制备一型极化树突状细胞的方法及其应用
CN105219725A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活肉瘤特异性免疫反应的试剂盒
CN105219728A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活乳腺癌特异性免疫反应的试剂盒
CN105219727A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活结直肠癌特异性免疫反应的试剂盒
CN106103701A (zh) * 2014-01-03 2016-11-09 富禾生医股份有限公司 改造的自然杀手细胞及其组成与用途
US10894065B2 (en) 2012-12-21 2021-01-19 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
CN115247149A (zh) * 2022-08-22 2022-10-28 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法
US11566228B2 (en) 2006-04-14 2023-01-31 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
US12097223B2 (en) 2011-11-30 2024-09-24 Astellas Institute For Regenerative Medicine Mesenchymal stromal cells and uses related thereto
US12209255B2 (en) 2012-07-12 2025-01-28 Astellas Institute For Regenerative Medicine Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US12465621B2 (en) 2011-11-30 2025-11-11 Astellas Institute For Regenerative Medicine Mesenchymal stromal cells and uses related thereto

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2841563B1 (en) * 2012-04-24 2019-06-12 Dan S. Kaufman Method for developing natural killer cells from stem cells
DE102014014993B4 (de) 2014-10-09 2017-02-02 Helga Schmetzer Verwendung von immunmodulatorisch wirksamen Kits zur immuntherapeutischen Behandlung von Patienten mit myeloischen Leukämien
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
KR102167548B1 (ko) * 2017-09-21 2020-10-19 한국생명공학연구원 자연살해세포의 제조방법 및 그의 용도
GB201810486D0 (en) 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
AU2019456283B2 (en) 2019-07-08 2023-06-08 Immunitybio, Inc. Mononuclear cell derived NK cells
US11547726B2 (en) * 2020-03-26 2023-01-10 Honed Life Sciences, Llc Enhancement of production of NK cells from stem cells
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
KR102292843B1 (ko) * 2020-12-29 2021-08-25 주식회사 온코인사이트 역분화줄기세포(iPSC) 유래 자연 살해 세포 및 이의 용도
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
WO2024047368A1 (en) * 2022-09-02 2024-03-07 Imperial College Innovations Limited Natural killer cells
KR20250127134A (ko) 2022-12-29 2025-08-26 아스텔라스세이야쿠 가부시키가이샤 조작된 자연 살상 세포 및 관련 방법
WO2025212519A1 (en) 2024-04-01 2025-10-09 Moonlight Bio, Inc. Dll3 binding proteins and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141703A1 (en) * 2003-11-19 2007-06-21 Stanley Edouard G Methods for producing blood products from pluripotent cells in cell culture

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2158295A (en) * 1994-06-15 1996-01-05 Systemix, Inc. Population of cells enriched for myeloid and/or lymphoid progenitors and methods of making and using
WO1998033891A1 (en) * 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
WO1998053048A1 (en) * 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
JP2001525176A (ja) * 1997-12-04 2001-12-11 デューク・ユニバーシティー Ｃｄ７＋ｃｄ３４−ｌｉｎ−造血細胞を単離し、使用する方法
FR2801056B1 (fr) * 1999-11-12 2003-03-28 Commissariat Energie Atomique Proteine presente a la surface des cellules souches hematopoietiques de la lignee lymphoide et des cellules nk, et ses applications
KR20020083634A (ko) * 2001-04-27 2002-11-04 크레아젠 주식회사 수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법
WO2003038072A1 (en) * 2001-10-31 2003-05-08 Universite Libre De Bruxelles Generation and use of new types of dendritic cells
US20060239962A1 (en) * 2002-12-04 2006-10-26 Banchereau Jacques F Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
ATE482725T1 (de) * 2003-04-01 2010-10-15 Us Dept Of Veteran S Affaires Auf stammzellen, vorläuferzellen oder targetzellen basierende behandlung von multiorganversagen.
WO2005085426A1 (ja) * 2004-03-04 2005-09-15 Tanabe Seiyaku Co., Ltd. 無フィ−ダ−分化用培地及び霊長類動物胚性幹細胞からの無フィ−ダ−分化方法
WO2006001120A1 (ja) * 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
ATE489455T1 (de) * 2004-10-07 2010-12-15 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
US20080166751A1 (en) * 2005-02-23 2008-07-10 Takayuki Asahara Method of Analyzing Dynamics in the Differentiation of Vascular Endothelial Progenitor Cells
CN101155914B (zh) * 2005-04-08 2013-03-06 阿戈斯治疗公司 树状细胞组合物和方法
EP1885845A2 (en) * 2005-06-01 2008-02-13 Wisconsin Alumni Research Foundation Method of forming dendritic cells from embryonic stem cells
SI1941027T1 (sl) * 2005-09-28 2014-11-28 Ipd-Theapeutics B.V. Postopki in sredstva za proliferacijo zarodnih celic in kasnejšo generacijo in ekspanzijo progenitorskih celic, kot tudi izdelava efektor celic kot kliničnih zdravil
KR102651433B1 (ko) 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
WO2008038279A2 (en) * 2006-09-25 2008-04-03 Kfir Nissan Force transducer and method
US20110151554A1 (en) * 2006-11-09 2011-06-23 Akira Yuo Method for culturing and subculturing primate embryonic stem cell, as well as method for inducing differentiation thereof
DE102006054041B3 (de) * 2006-11-16 2008-05-08 Pierburg Gmbh Regelvorrichtung für eine Verbrennungskraftmaschine
RU2536242C2 (ru) * 2007-09-28 2014-12-20 Антродженезис Корпорейшн Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров
KR101946785B1 (ko) * 2008-03-27 2019-02-12 아스테리아스 바이오세라퓨틱스, 인크. 영장류 다능성 줄기 세포의 조혈계 세포로의 분화
EP2712921B1 (en) 2008-05-06 2018-07-11 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
JP5748654B2 (ja) * 2008-05-06 2015-07-15 オカタ セラピューティクス， インコーポレイテッド 多能性幹細胞に由来する除核赤血球細胞を産生するための方法
KR101720961B1 (ko) * 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
CA3095576A1 (en) 2009-12-04 2011-06-09 Astellas Institute For Regenerative Medicine Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141703A1 (en) * 2003-11-19 2007-06-21 Stanley Edouard G Methods for producing blood products from pluripotent cells in cell culture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ELIAS T. ZAMBIDIS ET AL.: "Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells", 《BLOOD》, vol. 112, no. 9, 1 November 2008 (2008-11-01), pages 3601 - 3614 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566228B2 (en) 2006-04-14 2023-01-31 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
US8822218B2 (en) 2009-12-04 2014-09-02 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
US12097223B2 (en) 2011-11-30 2024-09-24 Astellas Institute For Regenerative Medicine Mesenchymal stromal cells and uses related thereto
US12465621B2 (en) 2011-11-30 2025-11-11 Astellas Institute For Regenerative Medicine Mesenchymal stromal cells and uses related thereto
US12209255B2 (en) 2012-07-12 2025-01-28 Astellas Institute For Regenerative Medicine Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US12076347B2 (en) 2012-12-21 2024-09-03 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
US12109239B2 (en) 2012-12-21 2024-10-08 Astellas Institute For Regenerative Medicine Methods for production of human hemogenic endothelial cells from pluripotent stem cells and compositions thereof
US11400118B2 (en) 2012-12-21 2022-08-02 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
US10894065B2 (en) 2012-12-21 2021-01-19 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
CN106103701B (zh) * 2014-01-03 2020-04-24 中央研究院 改造的自然杀手细胞及其组成与用途
CN106103701A (zh) * 2014-01-03 2016-11-09 富禾生医股份有限公司 改造的自然杀手细胞及其组成与用途
CN105219710B (zh) * 2014-06-05 2020-01-10 上海厚超生物科技有限公司 一种高杀伤活性的免疫细胞群的培养方法
CN105219710A (zh) * 2014-06-05 2016-01-06 上海厚超生物科技有限公司 一种高杀伤活性的免疫细胞群的培养方法
CN104711225A (zh) * 2015-04-09 2015-06-17 奥思达干细胞有限公司 Nk细胞的体外制备方法
CN104711225B (zh) * 2015-04-09 2018-05-22 奥思达干细胞有限公司 Nk细胞的体外制备方法
CN105219719A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活卵巢癌特异性免疫反应的试剂盒
CN105219727A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活结直肠癌特异性免疫反应的试剂盒
CN105219728A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活乳腺癌特异性免疫反应的试剂盒
CN105219725A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活肉瘤特异性免疫反应的试剂盒
CN105219726A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种高效制备一型极化树突状细胞的方法及其应用
CN105219718A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活前列腺癌特异性免疫反应的试剂盒
CN105219722A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活肾癌特异性免疫反应的试剂盒
CN105219723A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活胃癌特异性免疫反应的试剂盒
CN105219717A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种一型极化树突状细胞及其诱导方法和应用
CN105219716A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活头颈部癌特异性免疫反应的试剂盒
CN115247149A (zh) * 2022-08-22 2022-10-28 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法

Also Published As

Publication number Publication date
JP2016119910A (ja) 2016-07-07
KR20200083645A (ko) 2020-07-08
US20200131475A1 (en) 2020-04-30
EP2507365A4 (en) 2014-01-01
JP2013512673A (ja) 2013-04-18
US20150140657A1 (en) 2015-05-21
KR20250048382A (ko) 2025-04-08
CA3080368A1 (en) 2011-06-09
IN2012DN05053A (https=) 2015-10-09
JP2024177183A (ja) 2024-12-19
KR20190016602A (ko) 2019-02-18
WO2011068896A1 (en) 2011-06-09
JP2019083819A (ja) 2019-06-06
JP2022027790A (ja) 2022-02-14
EP2507365A1 (en) 2012-10-10
RU2012127811A (ru) 2014-01-10
BR112012014104A2 (pt) 2016-07-05
CA3095576A1 (en) 2011-06-09
US20120282693A1 (en) 2012-11-08
KR20120112511A (ko) 2012-10-11
CA2781969A1 (en) 2011-06-09
JP6013187B2 (ja) 2016-10-25
KR101947588B1 (ko) 2019-02-14
US8822218B2 (en) 2014-09-02
AU2010326027A1 (en) 2012-06-21
JP7343984B2 (ja) 2023-09-13
KR20210120136A (ko) 2021-10-06

Similar Documents

Publication Publication Date Title
JP7343984B2 (ja) ヒト胚性幹細胞由来血管芽細胞からナチュラルキラー細胞および樹状細胞を生成する方法
AU2020264375B2 (en) Method for developing natural killer cells from stem cells
US20220160778A1 (en) Mesenchymal stromal cells and uses related thereto
TWI812867B (zh) 利用血管母細胞產生間葉基質細胞之方法
KR20110006705A (ko) 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
KR20110016913A (ko) 혈관 콜로니 형성 세포 및 비-생착성 혈관 세포
US20050221482A1 (en) Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof
US20240166998A1 (en) Method for producing hematopoietic cells from stem cells using vascular organoids
HK40017506A (en) Method for developing natural killer cells from stem cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121212